NIH-funded research R01 grant

Personalized skin cancer risk feedback in community health centers

Official title: A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers

Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11179295 · Data updated 2026-11-12

This project gives adults served by community health centers personalized genetic risk information for skin cancer to help them protect their skin and find problems earlier.

More Skin Cancer research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionH. Lee Moffitt Cancer Ctr & Res Inst
NIH-funded
Lab location1 site (Tampa, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2025
Award (this year)$675,011
NIH project number5R01CA291735-02
Project IDNIH-11179295 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adults (21+) who receive care at participating federally qualified health centers and want to learn about their genetic risk for skin cancer.

Less likely to help

People under 21, those not served by the participating clinics, or individuals already diagnosed with advanced skin cancer are unlikely to benefit from joining this program.

What this research studies

If you join, you would receive information about your inherited risk for skin cancer based on a genetic test (including MC1R) and easy-to-read materials in English or Spanish. The program is being offered through federally qualified community health centers and is designed for people 21 and older. The team will track whether the personalized feedback changes prevention behaviors like sun protection, self-skin checks, and getting clinical skin exams. Staff will also study what makes it easier or harder to use this program in everyday clinic care so it can be used more widely.

Why it matters

Potential benefit: If successful, this approach could help people adopt better sun-protection and early-detection habits that lower their chances of advanced skin cancer.

How similar studies have gone: Earlier trials using MC1R-based risk feedback by this team showed interest, good follow-through, and improved prevention behavior among higher-risk participants, so this builds on promising prior results.

Where this research is happening

  • H. Lee Moffitt Cancer Ctr & Res Inst
    Tampa, United States
    Active

Researchers

  • Principal investigator: Kanetsky, Peter a — H. Lee Moffitt Cancer Ctr & Res Inst
  • Study coordinator: Kanetsky, Peter a

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.